We review some of the most recent developments concerning three genes involved in human cancer: p53, bcl2 and c-myc. Recent data have demonstrated that the bcl2 gene protects tumor cells from apoptosis induced by a variety of agents, including ionizing radiation, and is thus related to resistance to DNA-damaging therapeutic agents. The p53 tumor suppressor gene, however, has been related with growth arrest, apoptosis and thus with selective sensitivity to the killing effects of ionizing radiation and DNA-damaging drugs. This functional antagonism between the two genes was recently substantiated in molecular terms by demonstration of reciprocal down-regulation due to the presence of a p53-dependent transcription silencer in the untranslated region of the bc12 gene. Growth arrest in the G1 phase of the cell cycle and induction of apoptosis are two distinct and dissectable functions of p53: bcl2 is able to antagonize the induction of apoptosis by p53, but not the growth arrest in G1. However, coexpression of bcl2 and of the oncogene c-myc efficiently antagonizes effects of p53 on G1 arrest and apoptosis, thus suggesting a cooperation between the two oncogenes. In addition, c-myc disrupts other functions of genetic control in the early G1 phase of the cell cycle including the expression of D1 cyclin. We believe that knowledge of the functional/molecular interactions between these three genes involved in human cancer is a fundamental prerequisite to improve the knowledge on prognosis and to design innovative therapeutic approaches.
AmatiB.DaltonS.BrooksM.V.LittlewoodG.EvanL.LandH.: Transcriptional activation by human c-myc oncoprotein in yeast requires interaction with Max. Nature, 359: 423–426, 1992.
2.
BaffyG.MiyashitaT.WilliamsonJ.R.ReedJ.C.: Apoptosis induced by withdrawal of interleukin-3 (IL3) from IL3-dependent hematopoietic cell line is associated in repartitioning of intracellular calcium and is blocked by enforced bcl2 oncoprotein production. J. Biol. Chem., 268: 6511–6519,1993.
3.
BissonetteR.P.AcheverryF.MalaboutyA.GreenD.R.: Apoptotic cell death induced by c-myc is inhibited by bcl2. Nature, 359: 552–554,1992.
4.
BlackwoodE.M.EisemanJ.K.: Max: an helix-loop-helix zipper protein that forms a sequence-specific DNA binding complex with myc. Science, 250: 1149–1151, 1991.
5.
BrachmanD.G.BeckettM.GravesD.VokesE.WeichselbaumR.R.:p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res., 53: 3667–3669, 1993.
6.
BrendanD.P.CalderwoodS.K.: Increased sequence-specificp53 DNA binding activity after DNA damage is attenuated by phorbol esters. Oncogene, 8: 3055–3062,1993.
7.
CaellesC.HolmbergA.KarinM.:p53-dependent apoptosis in the absence of transcriptional activation target genes. Nature, 370: 220–223, 1994.
8.
ChiarugiV.MagnelliL.CinelliM.BasiG.: Apoptosis and the cell cycle. Cell. Mol. Biol. Res., 40: 603–612, 1994.
De JongD., PrinsF.A., MasonD.Y., ReedJ.C., Van OmnenG.B., KluinP.M.: Subcellular localization of the bcl2 protein in malignant and normal lymphoid cells. Cancer Res., 54: 256–260, 1994.
14.
EilersM.SchirmS.BishopJ.M.: The myc protein activates transcription of the alpha-protothymosin gene. EMBO J., 10: 133–141,1991.
15.
El DeityW.S., HarperJ.W., O'ConnorP.M., VelculescuV.E., CanmanC.E., KastanE., KohonK.W., ElledgeS.J., KinzlerK.W., VogelsteinB.: WAF1/CIP1 is induced inp53-mediated G1 arrest and apoptosis. Cancer Res., 54: 1169–1174, 1994.
16.
EvanG.I.WyllieC.S.GilbertT.D.LittlewoodH.L.BrooksM.WatersC.M.PennL.Z.HancockD.C.: Induction of apoptosis in fibroblasts by the c-myc protein. Cell, 68:122128, 1992.
17.
FanS.SmithM.L.RivetD.J.DubaD.ZhanQ.KohonK.W.FornaceA.J.O'ConnorP.M.: Disruption ofp53 function sensitize breast cancer MCF-7 cells to cisplatin and pentoxiphylline. Cancer Res., 55: 1649–1654, 1995.
18.
FanidiA.HarringtonE.A.EvanG.I.: Cooperative interaction between c-myc and bcl2 proto-oncogene. Nature, 359: 554–559, 1992.
19.
Fernandez-SarabiaM.J.BichoffJ.R.: bcl2 associates with ras-related protein R-ras-p23. Nature, 366: 554–559, 1992.
20.
GoruppiS.GustinchichS.BrancoliniC.LeeW.SchneiderC.: Dissection of myc domains involved in S phase induction in NIH/3T3 cells. Oncogene, 9: 1537–1544, 1994.
21.
HarperJ.W.AdamiG.R.WeiN.KeiomarsiG.ElledgeS.I.: Thep21-CDK-interacting protein CIP1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805–816, 1993.
22.
HochemberyD.OltvaiZ.M.YinX.M.MillimanC.KorsmeyerS.J.: bcl2 functions in an antioxidant pathway to prevent apoptosis. Cell, 75: 241–251, 1993.
23.
HochemberyD.ZutterM.HickeyW.NahamM.KorsmeyerS.J.: bcl2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc. Natl. Acad. Sci. U.S.A., 88: 6961–6965, 1991.
24.
HoffmanB.LiebermanD.A.: Molecular control of apoptosis: differentiation/growth arrest, primary cells, protooncogenes, and tumor suppressor genes as positive and negative regulators. Oncogene, 12: 1807–1812, 1994.
Jansen-DurrP.MeichleA.SteinerP. Pagano M., FinkeK., BotzJ., WessbecherJ., DraettaG., EilersM.: Differential modulation of cyclin gene expression by c-myc. Proc. Natl. Acad. Sci. U.S.A., 90: 3685–3689, 1993.
27.
JiangW.S.KahanM.ZhangY.CacaceA.WeinsteinI.B.: Overexpression of cyclin DI in rat fibroblasts causes abnormalities in growth control of cell cycle progression and gene expression. Oncogene, 8: 773–787, 1993.
KorsmeyerS.J.: bcl2 initiates a new category of oncogenes: regulators of cell death. Blood, 80: 876–886, 1992.
30.
LoweS.W.RuleyH.E.JacksT.HansonD.O.:p53-dependent apoptosis modulate the cytotoxicity of anticancer agents. Cell, 47: 957–967, 1993.
31.
LuL.HambyA.M., HajibagheriM.A., GeshmeissnerS.E., LuP.J.,PapadimitruJ.KrajeswkyS., ReesJ.C., WrightN.A.: bcl2 protein localizes to the chromosomes of mitotic nuclei and is correlated with the cell cycle in cultured epithelial cell lines. J. Cell. Sci., 107: 363–371, 1994.
32.
LuX.ParkS.H.ThompsonT.C.LaneD.P.: Ras-induced hyperplasia occurs with mutation ofp 53, but activated ras and myc together can induce carcinoma without p 53 mutation. Cell, 70: 153–161, 1992.
33.
MagnelliL.CinelliM.TurchettiA.ChiarugiV.P.: bc12 overexpression abolishes early calcium waveing preceding apoptosis in NIH/3T3 murine fibroblasts. Biochem. Biophys. Res. Commun., 204: 84–90, 1994.
34.
McDonnellT.J.KorsmeyerS.J.: Progression from lymphoid hyperplasia to high grade malignant lymphoma in mice transgenic for (t-14/18). Nature, 349: 254–256,1991.
35.
McllwrathA.VoseyP.RossG.M.BrownR.: Cell arrest and radiosensitivity of human tumor cell lines: dependence of wild-typep53 for radiosensitivity. Cancer Res., 54: 3718–3722, 1994.
36.
MiyashitaT.KrajewskiS.KrajewskaM.WangH.G.LinH.K.LiebermanD.A.HoffmanB.ReedJ.C.: Tumor suppressorp53 is a regulator of bcl2 and bax gene expression in vitro and in vivo. Oncogene, 9: 1799–1805, 1994.
37.
NowellP.C.CroceC.M.: Cytogenetics of neoplasia. In: Development and recognition of transformed cells, Green M. L and Hanaoka T. (Eds.), Plenum, New York, 1987.
38.
OswaldF.LovecH.MoroyT.LippM.: E2F-dependent regulation of human myc transactivation by cyclins D1 and A overrides tumor suppressor protein functions. Oncogene, 9: 2029–2036,1994.
39.
PhillippA.SchneiderA.VasrikLFinkeK.XiongY.BeachD.AlitaloK.EilersM.: Repression of cyclin DI: a novel function of myc? Mol. Cell. Biol., 14: 4032–4043, 1994.
40.
PowellS.N.DeFrankJ.S.ConnellP.PrefferF.DomkowskiD., FriendS.: Differential sensitivity of p 53- and p 53+ cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res., 55: 1643–1648, 1995.
41.
ReedJ.C.: bcl2 and the regulation of programmed cell death. J. Cell. Biol., 124: 1–6, 1994.
42.
ReyI.Taylor-HarrisP. Van Erp H., HallA.: R-ras interacts with ras-GTP, neurofibromin and c-raf but does not regulate cell growth and differentiation. Oncogene, 9: 685–692, 1994.
43.
RowleyR.: Reduction of radiation-induced G2 arrest by caffeine. Radiat. Res., 129: 224–227, 1992.
44.
RussellK.J.WiensL.W.DemersG.W.GallowayD.A.PlonS.E.GroudineM.: Abrogation of G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells. Cancer Res., 55:1639–1642, 1995.
45.
RyanJ.J.DanishR.GottliebelC.A.ClarkeM.F.: p53 induces apoptosis in G1 in hematopoietic cells. Mol. Cell. Biol., 13:711–719, 1993.
46.
RyanJ.J.ProchownikE.GottliebelC.A.ApelI.J.MerinoR.NunezG.ClarkeM.F.: c-myc and bcl2 modulate p53 function by altering p53 subcellular trafficking during cell cycle. Proc. Natl. Acad. Sci. U.S.A., 91: 5878–5882, 1994.
47.
Schultze-OsthoffK.WalczakH.DrogeW.KrammerP.H.: Cell nucleus and DNA fragmentation are not required for apoptosis. J. Cell. Biol., 127: 15–20, 1994.
48.
SelvakuranM.LinH.SjinR.ReedJ.C., LiebermanD.A., HoffmanB.: The novel primary response of gene myd-118 and the protooncogenes myb, myc, and bcl2 modulate transforming growth factor beta-1-induced apoptosis in myeloid leukemia. Mol. Cell. Biol., 14: 2352–2360, 1994.
SilvestriniR.VeneroniS.DaidoneM.G.BeniniE.BorracchiP.MezzettiM. Di FronzoG., RilkeF., VeronesiU.: The bcl2 protein: a prognostic indicator strongly related to p53 protein in lymphnode-negative breast cancer patients. J. Natl. Cancer Inst., 86:499–504, 1994.
51.
SlinchenmeyerW.I.NelsonG.W.SlebosR.J.KastaM.B.: Loss of ap53-associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res., 53: 4164–4168,1993.
52.
SmithM.L.ChenI.T.ZhanQ.BaeI.ChenC.Y.GilmerT.M.KastanM.B.O'ConnorP.M.FornaceA.J.Jr.: Interaction of thep53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science, 266: 1376–1380, 1994.
53.
StewardN.HicksG.ParaskevasF.MovatM.: Evidence for a second cell cycle block at G2/M byp53. Oncogene, 10: 109–115,1995.
54.
WangH.G.MiyashitaT.TokoyamaS.SatoT., TorigoeT., KrajewskiS., TanakaS., HarveyL., TroppmairJ., RappU.R.: Apoptosis regulation by interaction of bcl2 protein and rafl kinase. Oncogene, 9: 2751–2756, 1994.
55.
WangYSzekelyL.OkanI.KleiG.WimanK.G.:p53-triggered apoptosis is inhibited by bcl2 in a v-myc-induced cell lymphoma line. Oncogene, 8: 3427–3431, 1993.
56.
WeinertT.A.HartwellL.H.: The rad9 gene controls the cell cycle response to DNA damage in Saccharomyces cerevisiae. Science, 241: 317–321,1988.
57.
XiongYHannonG.ZhangH.CassoD.KobayashiR.BeachD.:p21 is universal inhibitor of cyclin kinases. Nature, 366: 701–705, 1993.
